Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, AIM ImmunoTech's Enterprise Value is $5.58 Mil.
AIM ImmunoTech's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $-14.37 Mil. Therefore, AIM ImmunoTech's EV-to-OCF for today is -0.39.
The historical rank and industry rank for AIM ImmunoTech's EV-to-OCF or its related term are showing as below:
AIM'
s EV-to-OCF Range Over the Past 10 Years
Min: -7.41 Med: -0.71 Max: 1.28
Current: -0.39
During the past 13 years, the highest EV-to-OCF of AIM ImmunoTech was 1.28. The lowest was -7.41. And the median was -0.71.
AIM's EV-to-OCF is ranked worse than 67.87% of 1407
companies
in the Biotechnology industry
Industry Median: -3.54
vs AIM: -0.39
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
AIM ImmunoTech's PE Ratio (TTM) for today is calculated as:
AIM ImmunoTech's share price for today is $0.2482.
AIM ImmunoTech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.047.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
AIM ImmunoTech EV-to-OCF Related Terms
AIM ImmunoTech EV-to-OCF Historical Data
* Premium members only.
The historical data trend for AIM ImmunoTech's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, AIM ImmunoTech's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AIM ImmunoTech EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AIM ImmunoTech's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where AIM ImmunoTech's EV-to-OCF falls into.
AIM ImmunoTech's current Enterprise Value is $5.58 Mil.
AIM ImmunoTech's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-14.37 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AIM ImmunoTech (AIM) has a EV-to-OCF of -0.39 as of Aug. 12, 2026. According to the industry distribution chart, AIM ImmunoTech ranks #955 out of 1407 companies in the Biotechnology industry, placing it in the top 67.9%.
Is AIM ImmunoTech's EV-to-OCF too high?
AIM ImmunoTech's current EV-to-OCF is -0.39. Based on the distribution chart, AIM ImmunoTech ranks #955 out of 1407 companies in the Biotechnology industry, which is below the industry midpoint. Overall, AIM ImmunoTech has a GF Score™ of 33/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does AIM ImmunoTech's EV-to-OCF compare to NIKI and PMCB?
According to the Biotechnology industry distribution chart, AIM ImmunoTech ranks #955 out of 1407 companies for EV-to-OCF. This places AIM ImmunoTech in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. AIM ImmunoTech's current EV-to-OCF is -0.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AIM ImmunoTech stock overvalued right now?
Based on GuruFocus' analysis, AIM ImmunoTech (AIM) is currently considered Possible Value Trap. The stock's GF Value™ is $2.24, compared to a current price of $0.25 — trading 88.9% below its estimated fair value. The current EV-to-OCF is -0.39. AIM ImmunoTech's overall GF Score™ is 33/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For AIM ImmunoTech (AIM), the current EV-to-OCF is -0.39 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AIM ImmunoTech (AIM) Overvalued in 2026?
Based on GuruFocus' analysis, AIM ImmunoTech stock appears to be undervalued.
The current stock price of $0.25 is trading 88.9% below its estimated GF Value™ of $2.24.
GuruFocus considers AIM ImmunoTech to be Possible Value Trap.
Key valuation signals for AIM:
EV-to-OCF: -0.39
GF Value™: $2.24 vs. price of $0.25 (88.9% below fair value)
No single metric tells the full story. See the AIM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders, and to treat cancers for which there are currently inadequate or unmet therapies. Its flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) molecule being developed for globally important cancers, viral diseases, and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS).
33GF Score
Get the complete analysis for AIM
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AIM has been successfully added to your 
